NEW YORK (GenomeWeb News) – Merck and BGI announced today that they will collaborate on the discovery and development of biomarkers and other genomic technologies.
The alliance combines Merck's expertise in drug discovery and development with BGI's sequencing and analytical capabilities.
Under the agreement, Whitehouse Station, NJ-based Merck and Shenzhen, China-based BGI can each propose projects to be undertaken. They also will each provide resources, expertise, samples, and other research materials needed for the collaboration.
"By working together we hope to apply BGI's comprehensive next-gen sequencing solutions to develop important new tools to aid drug development and enable effective tailoring of medicines to those patients most likely to respond," Jeffrey Chodakewitz, VP of late stage development at Merck Research Laboratories, said in a statement.
"This collaboration will bring mutual benefits to BGI and Merck in the next few years, but also support the development of new techniques that will benefit the medical and pharmaceutical industries as a whole," Ye Yin, president of the research and cooperation division of BGI, added.
Financial and other terms of the agreement were not disclosed.